Pacific Biosciences of California Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.5%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$167.8Mnext fiscal year
FY EPS (est.)
-$0.51next fiscal year
Monitoring Framework
Key Performance Indicators
Consumable Revenue Quarterly21.8MTarget: Consumables are expected to drive the majority of growth in 2026
Total Revenue Quarterly37.2MTarget: 165000000 to 175000000
Revio Shipments Quarterly15.0Target: Increase placements in strategic accounts
Vega Shipments Quarterly27.0Target: Broaden market reach and recover from academic funding pressure
Watch Items
- SPRQ-Nx Chemistry Commercial LaunchTrigger: Full commercial availability planned by early summer 2026Action: Monitor customer adoption rates, shipment delays, and impact on consumable pull-through
- Academic Funding Constraints in the AmericasTrigger: Continued soft instrument demand and regional funding pressureAction: Evaluate promotional pricing strategies and geographic revenue diversification
- Gross Margin CompressionTrigger: Non-GAAP gross margin falling below 37%Action: Assess computing component costs, promotional pricing impacts, and inventory adjustments
Research as of 19 Jun 2026